10-Q: QHSLab Reports Q1 2026 Results, Revenue Up 13%

QHSLab, Inc. reported Q1 2026 results with a 13% increase in revenue driven by its Integrated Service Program, despite a net loss.

Summary

• QHSLab, Inc. reported first-quarter 2026 revenue of $728,685, an increase of 13% compared to $645,419 in the first quarter of 2025.
• The company experienced a net loss of $103,906 for the three months ended March 31, 2026, compared to a net loss of $79,609 for the same period in 2025.
• Cash and cash equivalents decreased to $362,088 as of March 31, 2026, from $636,157 as of December 31, 2025.
• The company's accumulated deficit was $4,007,457 as of March 31, 2026.
• Disclosure controls and procedures were found to be ineffective as of March 31, 2026, due to a lack of adequate personnel with financial reporting experience.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautiously neutral to slightly negative filing due to the continued net loss and ineffective disclosure controls, despite revenue growth and a recent capital raise.

Positives

• Revenue increased by 13% to $728,685 in Q1 2026 compared to $645,419 in Q1 2025.
• The Integrated Service Program (ISP) revenue grew significantly by 130.5% to $374,501 from $162,502 in the prior year's quarter.
• Gross profit increased by $40,859 to $470,803, representing a 9.5% increase.
• Interest expense decreased significantly by $58,044 to $9,526 due to loan conversions and settlements.

Negatives

• The company reported a net loss of $103,906 for the quarter ended March 31, 2026, an increase from the $79,609 net loss in the prior year's quarter.
• Gross margin decreased from 66.6% in Q1 2025 to 64.6% in Q1 2026, primarily due to a change in revenue mix.
• Sales and marketing expenses increased by $74,025 to $218,424, reflecting increased investment in sales activities.
• General and administrative expenses increased by $52,299 to $207,822, due to increased payroll and operational costs.
• Cash and cash equivalents decreased by $274,069 during the quarter, ending at $362,088.
• The company's disclosure controls and procedures were deemed ineffective due to a lack of adequate personnel with financial reporting experience.

Risks

• The company's history of losses and current cash burn raise substantial doubt about its ability to continue as a going concern.
• Access to future funding may not be available on commercially reasonable terms, if at all.
• Additional issuances of equity or convertible debt could result in dilution to current shareholders.
• Default under any loan agreement could force the company to seek bankruptcy protection.
• The state of capital markets, impacted by global events, inflation, and other risks, could adversely affect the company's ability to raise funds.
• The company has net operating loss carryforwards of $4,007,457 which begin to expire in 2027, and their utilization may be limited by ownership change rules.

Future Outlook

The company expects its sales and marketing expenses to increase as it invests in building its customer base and launching additional products. Research and development expenses are also expected to increase as the company invests in expanding operations and developing new products and services. The company anticipates that existing working capital and anticipated cash flows will be adequate to fund operations over the next twelve months, but may seek additional equity or debt financing if necessary.

Management Comments

• Management believes the increase in gross profit reflects continued growth in the Company's operations.
• Management has identified corrective actions for the weakness in disclosure controls and will periodically reevaluate the ability to add personnel and implement improved review procedures as they can be supported by the business growth.

Industry Context

StockSavvy.ai notes that QHSLab operates in the value-based healthcare and informatics sector, focusing on providing tools for primary care physicians to manage chronic diseases and preventive care. The company's strategy to leverage its QHSLab software and diagnostic products for subscription-based revenue aligns with broader industry trends towards digital health solutions and remote patient monitoring, particularly those enabled by AI.

Comparison to Industry Standards

• The company's gross margin of 64.6% in Q1 2026 is a key metric. While specific industry benchmarks for this niche are not provided, a gross margin in this range would typically be considered healthy for a software and medical device hybrid company, though it has seen a slight decrease from the previous year.
• The increase in revenue, particularly from the Integrated Service Program (ISP), suggests successful market penetration and adoption of their service offerings, which is a positive indicator compared to competitors who may be slower to adapt to value-based care models.

Corporate Governance

Legal Proceedings

• There are no pending or threatened legal proceedings as of March 31, 2026.

Related Party Transactions

• Amounts due to related parties consist of cash advances received from the Company's principal shareholder.
• A portion of these advances has been converted into a loan to the principal shareholder at 10% interest, maturing March 31, 2027.
• As of March 31, 2026, $93,304 was due to related parties, recorded as a loan and accrued interest.
• The Company's CEO and principal shareholder is also a shareholder of MedScience and provides compensated services to MedScience.

Stakeholder Impact

• Shareholders: Potential dilution from future equity issuances, continued net losses impacting valuation, but also potential upside from revenue growth.
• Employees: Potential for increased workload due to insufficient personnel in financial reporting, but also potential for growth and new roles.
• Creditors: The company's going concern status may impact the certainty of debt repayment.
• Customers (PCPs): Continued provision of tools to increase revenue and manage chronic diseases.

Next Steps

• Continue to upgrade QHSLab to increase product sales.
• Solicit additional PCPs to increase revenue generation through QHSLab and AllergiEnd products.
• Introduce additional point-of-care diagnostics, treatments, and digital medicine programs.
• Management will periodically reevaluate the ability to add personnel and implement improved review procedures for disclosure controls.

Key Dates

Recommendation

The company shows revenue growth, particularly in its key service program, and has recently raised capital. However, the continued net loss, widening cash burn, and ineffective disclosure controls present significant risks. A 'hold' recommendation reflects a balance between the growth potential and the ongoing financial and operational challenges.

Keywords

QHSLab, 10-Q, Quarterly Report, Financial Statements, Revenue, Net Loss, Integrated Service Program, SaaS, Medical Device Technology, Going Concern, Disclosure Controls